Skip to main content
Tetra Bio-Pharma Inc. logo

Tetra Bio-Pharma Inc. — Investor Relations & Filings

Ticker · TBPMQ ISIN · CA88166Y1007 LEI · 5299000CYH3P8XC2UO53 TSX Manufacturing
Open in API
Filings indexed 720 across all filing types
Latest filing 2020-04-16 Report Publication Anno…
Country CA Canada
Listing TSX TBPMQ

About Tetra Bio-Pharma Inc.

https://tetrabiosciences.com/

Tetra Bio-Pharma is a biopharmaceutical company specializing in the discovery and development of cannabinoid-derived drugs and medicinal plant-based products. The company maintains an advanced pipeline encompassing biopharmaceuticals, natural health, and veterinary products. Clinical programs are focused on therapeutic areas such as inflammation, pain management (including alternatives to opioids), and ophthalmology. Tetra emphasizes rigorous clinical trials and scientific evidence, utilizing novel approaches, unique mechanisms of action, and high-quality delivery methods to address unmet patient needs.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Report Publication Announcement Classification · 95% confidence The document is a short notice indicating the filing of information under Form 51-101F1 related to the Corporation's Annual Information Form for the year ended December 31, 2019. It references the filing and provides a link to view the full report on SEDAR. The document itself does not contain substantive financial data or the full report but is an announcement of the filing. Given the short length (472 characters) and the nature of the content, this fits the criteria for a Report Publication Announcement (RPA) rather than the full Annual Report or other detailed filings.
2020-04-16 English
News release - English.pdf
Regulatory Filings
2020-04-15 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new streaming service called Mii.TV by Peeks Social Ltd. It contains no financial data, no regulatory form references, no meeting or voting information, and no mention of financial results or management changes. The content is a business update about a new product/service launch. The document length is short (2126 characters), and it is clearly an announcement rather than a report or filing. Therefore, it does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2020-04-14 English
Notice of the meeting and record date - French.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a notification from Computershare regarding the upcoming annual and extraordinary general meeting (AGM) of Tetra Bio Pharma Inc. It provides details such as the meeting date, registration deadlines, and voting information. The document is short (1281 characters) and serves as an announcement about the meeting rather than the meeting materials or results themselves. It does not contain financial data, management discussion, or voting results. Therefore, it fits best as a Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly a Regulatory Filing (RNS). However, since it is about the meeting details and voting rights, the most appropriate classification is DVA, which covers official results and voting rights announcements related to shareholder meetings. Confidence is high given the clear meeting-related content and absence of other report types.
2020-04-08 English
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 95% confidence The document is a notification addressed to Canadian Securities Regulatory Authorities regarding an upcoming Annual General and Special Meeting of Security Holders for Tetra Bio Pharma Inc. It provides details such as meeting type, record dates, meeting date, location, and proxy material handling. The document is short (1018 characters) and serves as an announcement about the meeting rather than the meeting materials or results themselves. It does not contain financial data, voting results, or detailed meeting content. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement about the meeting logistics and proxy materials, not the AGM materials or voting results themselves.
2020-04-08 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Tetra Bio-Pharma has secured a Type B meeting with the FDA regarding its drug HCC011. It discusses regulatory interactions, clinical trial plans, and orphan drug designation. There are no financial statements, earnings data, or detailed financial analysis. The content is an update on regulatory and clinical development progress rather than a financial report or detailed investor presentation. It does not fit into categories like Annual Report, Earnings Release, or Investor Presentation. It is a regulatory announcement about a meeting with the FDA, which is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement that does not fit other specific categories.
2020-04-06 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.